OUTCOMES OF 3D THORACO-LAPAROSCOPIC ESOPHAGECTOMY AND RADICAL LYMPH NODE DISSECTION FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AT K HOSPITAL
Main Article Content
Abstract
Background: This study aims to evaluate the treatment outcomes of patients with esophageal squamous cell carcinoma undergoing thoraco-laparoscopic esophagectomy and two-field or three-field lymph node dissection at K Hospital. Subjects and methods: Prospective descriptive study at K Hospital from October 2022 to December 2024 on patients with esophageal squamous cell carcinoma undergoing 3D thoracolaparoscopic esophagectomy and extended two-field lymph node dissection. Results: The mean age was 57.0 ± 7.0 years. 62.5% of patients underwent upfront surgery, while 37.5% received preoperative chemoradiotherapy. 93.8% underwent extended two-field lymph node dissection, and 6.3% underwent three-field dissection. One case of intraoperative tracheal perforation was recorded. The mean operation time of the thoracic phase was 172.4 ± 47.2 minutes. The average blood loss during the thoracic phase was 83.3 ± 56.4 mL.The most common postoperative complications were respiratory complications (27,5%) and grade I recurrent laryngeal nerve palsy (15%). After a mean follow-up duration of 15.1 ± 7.2 months, 9 cases of recurrence/metastasis were observed. Disease-free survival was significantly associated with lymph node metastasis status and disease stage (statistical significance with p < 0.05). Conclusion: 3D thoraco-laparoscopic esophagectomy and lymphadenectomy is a feasible, safe, and effective approach for esophageal cancer treatment in Vietnam. Managing complications and ensuring comprehensive postoperative follow-up are crucial to improving treatment outcomes.
Article Details
Keywords
Esophageal squamous cell carcinoma, 3D thoracolaparoscopic esophagectomy, lymph node dissection in esophageal cancer
References


2. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22): 2074-2084. doi:10.1056/ NEJMoa1112088


3. Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2023;21(4):393-422. doi:10.6004/ jnccn.2023.0019


4. Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus. 2017;14(1):1-36. doi:10.1007/s10388-016-0551-7


5. Mine S, Tanaka K, Kawachi H, et al. Japanese Classification of Esophageal Cancer, 12th Edition: Part I. Esophagus Off J Jpn Esophageal Soc. 2024; 21(3): 179-215. doi:10.1007/s10388-024-01054-y


6. Koterazawa Y, Oshikiri T, Takiguchi G, et al. Prophylactic cervical lymph node dissection in thoracoscopic esophagectomy for esophageal cancer increases postoperative complications and does not improve survival. Ann Surg Oncol. 2019;26:2899-2904.

7. Tsunoda S, Tsubosa Y, Sasaki K, et al. A multicenter randomized controlled trial of esophagectomy with or without prophylactic supraclavicular node dissection: a phase 3 trial (JCOG2013, MODERN3). Jpn J Clin Oncol. 2023;53(9):858-862. doi:10.1093/jjco/hyad071


8. Xin N, Ding X, Huang K, et al. Three-dimension versus two-dimension video-assisted thoracoscopic surgery for esophageal cancer: a meta-analysis. Transl Cancer Res. 2021;10(7):3448-3457. doi:10.21037/tcr-21-644


9. Kang LY, Lee WJ, Chen SS. Using three-dimensional versus two-dimensional laparoscopy in sleeve gastrectomy: A case matched comparison. Formos J Surg. 2024;57(2):63. doi:10.1097/FS9.0000000000000100

